Dietary methionine restriction in cancer development and antitumor immunity
Trends in Endocrinology & Metabolism · 2024-05 · 35 (5) · 400-412
DOI: 10.1016/j.tem.2024.01.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2024-05. Verfasst von Ming Ji und 2 weiteren Autor:innen. Beteiligte Einrichtung: Signal Transduction Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA. Hauptthemen laut MEDLINE: Methionine, Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health, National Institute of Environmental Health Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Signal Transduction Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
- Signal Transduction Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA. Electronic address: lix3@niehs.nih.gov.
Förderung
- Intramural NIH HHS
- National Institutes of Health
- National Institute of Environmental Health Sciences
Zitieren
APA
Ji, M., Xu, Q., & Li, X. (2024). Dietary methionine restriction in cancer development and antitumor immunity. Trends in Endocrinology & Metabolism, 35(5), 400-412. https://doi.org/10.1016/j.tem.2024.01.009
Vancouver
Ji M, Xu Q, Li X. Dietary methionine restriction in cancer development and antitumor immunity. Trends in Endocrinology & Metabolism. 2024;35(5):400-412. doi:10.1016/j.tem.2024.01.009
BibTeX
@article{Ji2024,
author = {Ji, Ming and Xu, Qing and Li, Xiaoling},
title = {Dietary methionine restriction in cancer development and antitumor immunity},
journal = {Trends in Endocrinology & Metabolism},
year = {2024},
volume = {35},
number = {5},
pages = {400--412},
doi = {10.1016/j.tem.2024.01.009}
}
EUVIMED